Table 1.
Description of Included Trials
| First Author, Year (Ref.) | Location, Setting | Sample, n | Population | Age, y | Ethnicity | Duration, mo | Interventions |
|---|---|---|---|---|---|---|---|
| Barnhart, 1999 (27) | United States, academic hospital | 66 | Perimenopausal women with altered mood and well-being | 45–55 | 82% CC, 15% AA, 2% AS | 6 | DHEA (oral, 50 mg) vs placebo |
| Baulieua, 2000 (6) | France, NR | 140 | Healthy postmenopausal women | 60–79 | NR | 12 | DHEA (oral, 50 mg) vs placebo |
| Bloch, 2013 (28) | Israel, academic hospital | 25 | Health postmenopausal women with HSDD | 54 | NR | 1.5 | DHEA (oral, 100 mg) vs placebo |
| Carranza-Lira, 2002 (29) | Mexico, academic hospital | 20 | Healthy postmenopausal women | 54 | NR | 1 | DHEA (oral, 35 mg) vs placebo |
| Casson, 1995 (30) | United States, academic hospital | 11 | Healthy postmenopausal women | 56 | NR | 1 | DHEA (oral, 50 mg) vs placebo |
| Dayal, 2005 (31) | United States, academic hospital | 50 | Healthy postmenopausal women | 57 | NR | 3 | DHEA (oral, 50 mg) vs placebo |
| Finckh, 2005 (32) | Switzerland, academic hospital | 52 | Postmenopausal women with fibromyalgia | 59 | NR | 3 | DHEA (oral, 50 mg) vs placebo |
| Gómez-Santos, 2012 (33) | Spain, academic hospital | 61 | Healthy postmenopausal women | 51.5 | NR | 3 | DHEA (oral, 100 mg) vs placebo |
| Igwebuike, 2008 (34) | United States, academic hospital | 31 | Sedentary, postmenopausal women | 64 | 100% CC | 3 | DHEA (oral, 50 mg) vs placebo |
| Jankowski, 2006 (35) | United States, academic hospital | 70 | Healthy postmenopausal women | 68 | NR | 12 | DHEA (oral, 50 mg) vs placebo |
| Kenny, 2010 (36) | United States, major medical institution | 99 | Postmenopausal women with low DHEAS levels, low bone mass, and frailty | 76.6 | 91% CC, 6% AA, 1% HI, 2% other | 6 | DHEA (oral, 50 mg) vs placebo |
| Kritz-Silverstein, 2008 (7) | United States, clinical research facility | 115 | Healthy postmenopausal women | 68 | NR | 12 | DHEA (oral, 50 mg) vs placebo |
| Lasco, 2001 (37) | Italy, academic hospital | 20 | Healthy adrenal-androgen-deficient postmenopausal women | 57 | NR | 12 | DHEA (oral, 25 mg) vs placebo |
| Morales, 1994 (8) | United States, academic hospital | 17 | Healthy perimenopausal women | 54.5 | NR | 6 | DHEA (oral, 50 mg) vs placebo |
| Morales, 1998 (16) | United States, academic hospital | 10 | Healthy nonobese, advanced age, postmenopausal women | 54.5 | NR | 6 | DHEA (oral, 100 mg) vs placebo |
| Mortola, 1990 (9) | United States, academic hospital | 6 | Healthy postmenopausal women | 46–61 | NR | 1 | DHEA (oral, 1600 mg) vs placebo |
| Nair, 2006 (14) | United States, academic hospital | 57 | Elderly postmenopausal women with low DHEA levels | 69 | NR | 24 | DHEA (oral, 50 mg) vs placebo |
| Panjari, 2009 (10, 38) | Australia, academic hospital | 93 | Healthy postmenopausal women with low libido | 54 | NR | 12 | DHEA (oral, 50 mg) vs placebo |
| Srinivasan, 2010 (39) | United States, academic hospital | 57 | Healthy postmenopausal women with low levels of DHEAS | 69 | NR | 24 | DHEA (oral, 50 mg) vs placebo |
| von Mühlen, 2008 (40) | United States, academic hospital | 115 | Healthy postmenopausal women | 68.5 | NR | 12 | DHEA (oral, 50 mg) vs placebo |
| Weiss, 2009 (41) | United States, academic hospital | 58 | Healthy postmenopausal women | 70 | 96% CC, 4% AA | 12 | DHEA (oral, 50 mg) vs placebo |
| Wolf, 1997 (11) | Germany, academic hospital | 15 | Healthy postmenopausal women | 69.1 | NR | 1.5 | DHEA (oral, 50 mg) vs placebo |
Abbreviations: NR, not reported; HSDD, hypoactive sexual desire disorder; CC, Caucasian; AA, African American; AS, Asian; HI, Hispanic. Age is expressed as mean or range.